TapImmune (NASDAQ:MRKR) posted its quarterly earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.12, Bloomberg Earnings reports.

Shares of MRKR traded up $0.06 on Thursday, reaching $6.92. 8,955 shares of the company’s stock were exchanged, compared to its average volume of 266,289. The company has a market cap of $314.58 million, a price-to-earnings ratio of -5.97 and a beta of -0.32. TapImmune has a 12 month low of $2.58 and a 12 month high of $13.55.

Separately, Piper Jaffray Companies initiated coverage on shares of TapImmune in a research note on Monday, October 22nd. They set a “neutral” rating for the company.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/11/15/tapimmune-mrkr-releases-earnings-results-beats-expectations-by-0-12-eps.html.

About TapImmune

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.

Featured Story: Stock Split

Earnings History for TapImmune (NASDAQ:MRKR)

Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.